TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Pharmacogenomics Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Pharmacogenomics Market: Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Pharmacogenomics Market Size Estimation
Chapter 4. Pharmacogenomics Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Pharmacogenomics Market Factor Analysis
5.1 Porters Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Pharmacogenomics Market, by Technology
6.1 Introduction
6.2 Microarray
Market Estimates & Forecast, 2020-2025
6.3 Sequencing
Market Estimates & Forecast, 2020-2025
6.3.1 Sanger Sequencing
6.3.2 Pyrosequencing
6.3.3 Next-Generation Sequencing
6.3.4 Others
6.4 Polymerase Chain Reaction
Market Estimates & Forecast, 2020-2025
6.5 Others
Chapter 7. Global Pharmacogenomics Market, by Application
7.1 Introduction
7.2 Oncology
Market Estimates & Forecast, 2020-2025
7.2.1 Breast Cancer
7.2.2 Lung Cancer
7.2.3 Others
7.3 Cardiology
Market Estimates & Forecast, 2020-2025
7.4 Neurological Disorders
Market Estimates & Forecast, 2020-2025
7.5 Others
Market Estimates & Forecast, 2020-2025
Chapter 8 Global Pharmacogenomics Market, by End User
8.1 Introduction
8.2 Hospitals and clinics
Market Estimates & Forecast, 2020-2025
8.3 Research Organizations
Market Estimates & Forecast, 2020-2025
8.4 Academic Institute
Market Estimates & Forecast, 2020-2025
8.5 Others
Market Estimates & Forecast, 2020-2025
Chapter 9. Global Pharmacogenomics Market, by Region
9.1 Introduction
9.2 America
9.2.1 North America
9.2.1.1 US
9.2.1.1 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 UK
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia Pacific
9.5 The Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of the Middle East & Africa
Chapter 10 Company Landscape: Pharmacogenomics Market
10.1 Introduction
10.2 Pharmacogenomics Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments
Chapter 11 Company Profiles
11.1 Myriad Genetics, Inc.
11.1.1 Company Overview
11.1.2 Product Overview
11.1.3 Financials
11.1.4 Key Developments
11.1.5 SWOT Analysis
11.2 23andMe, Inc.
11.2.1 Company Overview
11.2.2 Product Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 Pathway Genomics
11.3.1 Company Overview
11.3.2 Product Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 GeneTech
11.4.1 Company Overview
11.4.2 Product/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 GeneDx.
11.5.1 Overview
11.5.2 Company Overview
11.5.3 Product Overview
11.5.4 Financial overview
11.5.5 Key Developments
11.6 Future Science Group
11.6.1 Overview
11.6.2 Company Overview
11.6.3 Product Overview
11.6.4 Financial Overview
11.6.5 Key Developments
11.7 Teva Pharmaceutical Industries Ltd.
11.7.1 Overview
11.7.2 Product Overview
11.7.3 Financials
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 Assurex Health, Inc.
11.8.1 Overview
11.8.2 Product Overview
11.8.3 Financials
11.8.4 Key Developments
11.8.5 SWOT Analysis
11.9 Others
Chapter 12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEOโs View Point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of Pharmaceutical industry
Chapter 13 Appendix
LIST OF TABLES
Table 1 Pharmacogenomics Industry Synopsis, 2020-2025
Table 2 Global Pharmacogenomics Market Estimates and Forecast, 2020-2025, (USD Million)
Table 3 Global Pharmacogenomics Market by Region, 2020-2025, (USD Million)
Table 4 Global Pharmacogenomics Market by Technology, 2020-2025, (USD Million)
Table 5 Global Pharmacogenomics Market by Application, 2020-2025, (USD Million)
Table 6 Global Pharmacogenomics Market by End Users, 2020-2025, (USD Million)
Table 7 North America Pharmacogenomics Market by Technology, 2020-2025, (USD Million)
Table 8 North America Pharmacogenomics Market by Application, 2020-2025, (USD Million)
Table 9 North America Pharmacogenomics Market by End Users, 2020-2025, (USD Million)
Table 10 US Pharmacogenomics Market by Technology, 2020-2025, (USD Million)
Table 11 US Pharmacogenomics Market by Application, 2020-2025, (USD Million)
Table 12 US Pharmacogenomics Market by End Users, 2020-2025, (USD Million)
Table 13 Canada Pharmacogenomics Market by Technology, 2020-2025, (USD Million)
Table 14 Canada Pharmacogenomics Market by Application, 2020-2025, (USD Million)
Table 15 Canada Pharmacogenomics Market by End Users, 2020-2025, (USD Million)
Table 16 South America Pharmacogenomics Market by Technology, 2020-2025, (USD Million)
Table 17 South America Pharmacogenomics Market by Application, 2020-2025, (USD Million)
Table 18 South America Pharmacogenomics Market by End Users, 2020-2025, (USD Million)
Table 19 Europe Pharmacogenomics Market by Technology, 2020-2025, (USD Million)
Table 20 Europe Pharmacogenomics Market by Application, 2020-2025, (USD Million)
Table 21 Europe Pharmacogenomics Market by End Users, 2020-2025, (USD Million)
Table 22 Western Europe Pharmacogenomics Market by Technology, 2020-2025, (USD Million)
Table 23 Western Europe Pharmacogenomics Market by Application, 2020-2025, (USD Million)
Table 24 Western Europe Pharmacogenomics Market by End Users, 2020-2025, (USD Million)
Table 25 Eastern Europe Pharmacogenomics Market by Technology, 2020-2025, (USD Million)
Table 26 Eastern Europe Pharmacogenomics Market by Application, 2020-2025, (USD Million)
Table 27 Eastern Europe Pharmacogenomics Market by End Users, 2020-2025, (USD Million)
Table 28 Asia Pacific Pharmacogenomics Market by Technology, 2020-2025, (USD Million)
Table 29 Asia Pacific Pharmacogenomics Market by Application, 2020-2025, (USD Million)
Table 30 Asia Pacific Pharmacogenomics Market by End Users, 2020-2025, (USD Million)
Table 31 Middle East & Africa Pharmacogenomics Market by Technology, 2020-2025, (USD Million)
Table 32 Middle East & Africa Pharmacogenomics Market by Application, 2020-2025, (USD Million)
Table 33 Middle East & Africa Pharmacogenomics Market by End Users, 2020-2025, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Pharmacogenomics Market
Figure 3 Segmentation Market Dynamics for Global Pharmacogenomics Market
Figure 4 Global Pharmacogenomics Market Share, by Technology 2020
Figure 5 Global Pharmacogenomics Market Share, by Application 2020
Figure 6 Global Pharmacogenomics Market Share, by End Users, 2020
Figure 7 Global Pharmacogenomics Market Share, by Region, 2020
Figure 8 North America Pharmacogenomics Market Share, by Country, 2020
Figure 9 Europe Pharmacogenomics Market Share, by Country, 2020
Figure 10 Asia Pacific Pharmacogenomics Market Share, by Country, 2020
Figure 11 Middle East & Africa Pharmacogenomics Market Share, by Country, 2020
Figure 12 Global Pharmacogenomics Market: Company Share Analysis, 2020 (%)
Figure 14 Myriad Genetics, Inc.: Key Financials
Figure 15 Myriad Genetics, Inc.: Segmental Revenue
Figure 16 Myriad Genetics, Inc.: Geographical Revenue
Figure 17 23andMe, Inc.: Key Financials
Figure 18 23andMe, Inc.: Segmental Revenue
Figure 19 23andMe, Inc.: Geographical Revenue
Figure 20 Pathway Genomics: Key Financials
Figure 21 Pathway Genomics: Segmental Revenue
Figure 22 Pathway Genomics: Geographical Revenue
Figure 23 GeneTech: Key Financials
Figure 24 GeneTech: Segmental Revenue
Figure 25 GeneTech: Geographical Revenue
Figure 26 GeneDx. : Key Financials
Figure 27 GeneDx. : Segmental Revenue
Figure 28 GeneDx. : Geographical Revenue
Figure 29 Future Science Group: Key Financials
Figure 30 Future Science Group: Segmental Revenue
Figure 31 Future Science Group: Geographical Revenue
Figure 32 Teva Pharmaceutical Industries Ltd.: Key Financial
Figure 33 Teva Pharmaceutical Industries Ltd.: Segmental Revenue
Figure 34 Teva Pharmaceutical Industries Ltd.: Geographical Revenue
Figure 35 Assurex Health, Inc..: Key Financials
Figure 36 Assurex Health, Inc.: Segmental Revenue
Figure 37 Assurex Health, Inc.: Geographical Revenue